Premium
Bone alkaline phosphatase measured with a new immunoradiometric assay in patients with metabolic bone diseases
Author(s) -
Gonnelli S.,
Cepollaro C.,
Montagnani A.,
Monaci G.,
Campagna M. S.,
Franci M. B.,
Gennari C.
Publication year - 1996
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1046/j.1365-2362.1996.142304.x
Subject(s) - bone remodeling , alkaline phosphatase , medicine , osteocalcin , endocrinology , immunoradiometric assay , osteoporosis , parathyroid hormone , hyperparathyroidism , chemistry , calcium , radioimmunoassay , enzyme , biochemistry
We have investigated the clinical utility of a new quantitative two‐site radioimmunometric assay specific for bone alkaline phosphatase (B‐ALP) in 219 healthy control subjects and in 264 patients with various metabolic bone diseases. B‐ALP was compared with total alkaline phosphatase (T‐ALP) and with osteocalcin (BGP). B‐ALP increased linearly with age in both sexes. In postmenopausal normal women B‐ALP increased by 82% compared with premenopausal normal women, whereas the differences between pre‐ and postmenopausal women for T‐ALP and BGP were 18% and 30% respectively. As assessed by Z ‐score, the highest values of B‐ALP were found in patients with Paget's disease of bone, bone metastases or hyperparathyroidism and in patients on maintenance haemodialysis. In osteoporotic patients, B‐ALP, but not T‐ALP, showed a slight but significant ( P < 0.05) difference compared with normal women. On the basis of bone turnover, osteoporotic patients were divided into two groups: high turnover and low turnover; B‐ALP, like BGP, was significantly ( P < 0.01) higher in patients with high turnover. In conclusion, B‐ALP, measured by this new method, can be considered a sensitive marker of bone turnover and could be especially useful in identifying women at risk of developing osteoporosis.